title: Screening for prostate cancer: time to put all the data on the table.
authors.affiliation: Melbourne Oncology Group, Cabrini Medical Centre, Malvern 3144, Australia AMREP Department of Medicine, Monash University, Australia ian.haines@monash.edu.
authors.forename: Ian E
authors.initials: IE
authors.lastname: Haines
authors.affiliation: Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA Arizona Cancer Center and BIO5 Institute, Tucson, AZ, USA.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Ablin
authors.affiliation: Atomic Oncology, Newport, NSW 2106, Australia.
authors.forename: George L Gabor
authors.initials: GL
authors.lastname: Miklos
mesh_terms: D000368:Aged; D001315:Australia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000706:statistics & numerical data; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000191:economics / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment
chemical_list: D017430:Prostate-Specific Antigen